There are currently 7 active clinical trials seeking participants for Pulmonary Embolism research studies. The states with the highest number of trials for Pulmonary Embolism participants are .
Inari VISION Registry
NCT06600542
Recruiting
This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Southmead Hospital Bristol, Bristol, Not set +3 locations
Conditions: Pulmonary Embolism
Register for Updates
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370
Recruiting
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE. Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +71 locations
Conditions: Pulmonary Embolism
Register for Updates
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
NCT04798261
Recruiting
The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Long Beach Medical Center, Long Beach, California +61 locations
Conditions: Pulmonary Embolism
Register for Updates
Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study
NCT05881798
Recruiting
This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Parc Tauli, Sabadell, Not set +1 locations
Conditions: Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism
Register for Updates
GEKO Venous Thromboembolism Prevention Study
NCT05476913
Recruiting
This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to receive either standard of care (Intermittent Pneumatic Compression) or geko™ neuromuscular electrostimulation device. The aim is to assess the prevention of VTE during a follow-up period of 90 days (three months) post-randomisation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: West Suffolk Hospital, Bury St Edmunds, Suffolk +17 locations
Conditions: Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
Register for Updates
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +184 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +218 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates